Cancer Letters · 2024 · 50 citations · 85 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor MicroenvironmentCancer ImmunotherapyCell-based ImmunotherapyCell-mediated ImmunityChimeric Antigen Receptor T-cell TherapyImmunotherapy For Solid TumorsT Cell ActivationAcute Lymphoblastic Leukemia TreatmentAdoptive ImmunotherapyCar T Cell TrialsChimeric Antigen Receptor T-cell Therapy ToxicityComplete Response AssessmentSolid Tumor Car T-cell TherapySolid Tumor Cell TherapyT-cell Therapy
Chimeric antigen receptor T (CAR-T) cell therapy, as an adoptive immunotherapy, is playing an increasingly important role in the treatment of malignant tumors. CAR-T cells are referred to as "living drugs" as they not only target tumor cells directly, but also induce long-term immune memory that has the potential to provide long-lasting protection. CD19.CAR-T cells have achieved complete response rates of over 90 % for acute lymphoblastic leukemia and over 60 % for non-Hodgkin's lymphoma. However, the response rate of CAR-T cells in the treatment of solid tumors remains extremely low and the side effects potentially severe. In this review, we discuss the limitations that the solid tumor microenvironment poses for CAR-T application and the solutions that are being developed to address these limitations, in the hope that in the near future, CAR-T cell therapy for solid tumors can attain the same success rates as are now being seen clinically for hematological malignancies.
85
A2A adenosine receptor protects tumors from antitumor T cells
Akio Ohta, Elieser Gorelik, Simon J. Prasad et al. · Proceedings of the National Academy of Sciences · 2006 · 1K citations
Medicine, Immunology, Oncology +16